Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3387-3391, July 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reddy, B. S.
Right arrow Articles by Rao, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reddy, B. S.
Right arrow Articles by Rao, C. V.
[Cancer Research 59, 3387-3391, July 15, 1999]
© 1999 American Association for Cancer Research

Carcinogenesis

Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process1

Bandaru S. Reddy2, Toshihiko Kawamori, Ronald A. Lubet, Vernon E. Steele, Gary J. Kelloff and Chinthalapally V. Rao

Division of Nutritional Carcinogenesis, American Health Foundation, Valhalla, New York 10595 [B. S. R., T. K., C. V. R.], and Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland 20892 [R. A. L., V. E. S., G. J. K.]

Epidemiological and model studies with laboratory animals have provided evidence that nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer. Sulindac, a nonsteroidal anti-inflammatory drug, has been shown to inhibit azoxymethane (AOM)-induced colon carcinogenesis in rats when administered continuously before, during, and after carcinogen treatment (initiation and postinitiation periods) or when given continuously beginning 14 weeks after carcinogen administration (promotion/progression stage). The present study was designed to investigate the chemopreventive efficacy of sulindac sulfone (exisulind), the sulfone metabolite of sulindac, when administered during the promotion/progression stage of colon carcinogenesis in comparison to the effect during the initiation and postinitiation periods. We have also studied the modulating effect of exisulind on colonic tumor apoptosis. At 5 weeks of age, groups of male F344 rats were fed diets containing 0%, 0.06%, and 0.12% exisulind. At 7 weeks of age, groups of animals were injected s.c. with AOM (15 mg/kg body weight, once weekly for 2 weeks). Animals intended for the promotion/progression study and receiving 0% exisulind were switched to an experimental diet containing 0.12% exisulind at 14 weeks after the second AOM treatment. All rats remained on their respective dietary regimens until the termination of the study, 50 weeks after the second AOM injection. Colon tumors were evaluated histopathologically for tumor type. Administration of 0.06% and 0.12% exisulind during the initiation and postinitiation periods significantly inhibited the incidence and multiplicity of invasive and/or noninvasive adenocarcinomas of the colon. The inhibition of colon tumorigenesis by exisulind was associated with a significant retardation of body weight gain shortly after sulfone administration and increased apoptosis in the colon tumors. In contrast, administration of the higher dose (0.12%) of exisulind during the promotion/progression stage had only minimal effects on colon tumorigenesis and apoptosis in the colon tumors, suggesting that early administration, but not late administration, may be required for chemopreventive efficacy of this drug.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. Namba, T. Homan, T. Nishimura, S. Mima, T. Hoshino, and T. Mizushima
Up-regulation of S100P Expression by Non-steroidal Anti-inflammatory Drugs and Its Role in Anti-tumorigenic Effects
J. Biol. Chem., February 13, 2009; 284(7): 4158 - 4167.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Mima, M. Takehara, H. Takada, T. Nishimura, T. Hoshino, and T. Mizushima
NSAIDs suppress the expression of claudin-2 to promote invasion activity of cancer cells
Carcinogenesis, October 1, 2008; 29(10): 1994 - 2000.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence
Clin. Cancer Res., October 1, 2007; 13(19): 5965 - 5973.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al.
Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. P. Ciolino, C. J. MacDonald, O. S. Memon, S. E. Bass, and G. C. Yeh
Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro
Carcinogenesis, August 1, 2006; 27(8): 1586 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K.-i. Tanaka, W. Tomisato, T. Hoshino, T. Ishihara, T. Namba, M. Aburaya, T. Katsu, K. Suzuki, S. Tsutsumi, and T. Mizushima
Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced Apoptosis
J. Biol. Chem., September 2, 2005; 280(35): 31059 - 31067.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Hughes-Fulford, R. R. Tjandrawinata, C.-F. Li, and S. Sayyah
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells
Carcinogenesis, September 1, 2005; 26(9): 1520 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Mima, S. Tsutsumi, H. Ushijima, M. Takeda, I. Fukuda, K. Yokomizo, K. Suzuki, K. Sano, T. Nakanishi, W. Tomisato, et al.
Induction of Claudin-4 by Nonsteroidal Anti-inflammatory Drugs and Its Contribution to Their Chemopreventive Effect
Cancer Res., March 1, 2005; 65(5): 1868 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin
Carcinogenesis, May 1, 2004; 25(5): 713 - 722.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. M Herendeen and C. Lindley
Use of NSAIDs for the Chemoprevention of Colorectal Cancer
Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. L. Rice, J. Kelloff, H. Sullivan, L. J. Driggers, K. S. Beard, S. Kuwada, G. Piazza, and D. J. Ahnen
Sulindac metabolites induce caspase- and proteasome-dependent degradation of {beta}-catenin protein in human colon cancer cells
Mol. Cancer Ther., September 1, 2003; 2(9): 885 - 892.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Yang, K. Fan, N. Kurihara, H. Shinozaki, B. Rigas, L. Augenlicht, L. Kopelovich, W. Edelmann, R. Kucherlapati, and M. Lipkin
Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations
Carcinogenesis, March 1, 2003; 24(3): 605 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne
Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma
Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. J. Thun, S. J. Henley, and C. Patrono
Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues
J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. Vogiagis, W. Brown, E. M. Glare, and P. E. O'Brien
Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels
Carcinogenesis, June 1, 2001; 22(6): 869 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Bigler, J. Whitton, J. W. Lampe, L. Fosdick, R. M. Bostick, and J. D. Potter
CYP2C9 and UGT1A6 Genotypes Modulate the Protective Effect of Aspirin on Colon Adenoma Risk
Cancer Res., May 1, 2001; 61(9): 3566 - 3569.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
G. A. Piazza, W. J. Thompson, R. Pamukcu, H. W. Alila, C. M. Whitehead, L. Liu, J. R. Fetter, W. E. Gresh Jr., A. J. Klein-Szanto, D. R. Farnell, et al.
Exisulind, a Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis
Cancer Res., May 1, 2001; 61(10): 3961 - 3968.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
D. A. Maria, O. G. Ribeiro, K. F. Pizzocaro, M. De Franco, W. K. Cabrera, N. Starobinas, V. Gallois, M. Siqueira, M. Seman, and O. M. Ibanez
Resistance to melanoma metastases in mice selected for high acute inflammatory response
Carcinogenesis, February 1, 2001; 22(2): 337 - 342.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Richter, M. Weiss, I. Weinberger, G. Furstenberger, and B. Marian
Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors
Carcinogenesis, January 1, 2001; 22(1): 17 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. F. Souza, K. Shewmake, D. G. Beer, B. Cryer, and S. J. Spechler
Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells
Cancer Res., October 1, 2000; 60(20): 5767 - 5772.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
I. Shureiqi, D. Chen, J. J. Lee, P. Yang, R. A. Newman, D. E. Brenner, R. Lotan, S. M. Fischer, and S. M. Lippman
15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells
J Natl Cancer Inst, July 19, 2000; 92(14): 1136 - 1142.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Rahman, D. K. Dhar, R. Masunaga, A. Yamanoi, H. Kohno, and N. Nagasue
Sulindac and Exisulind Exhibit a Significant Antiproliferative Effect and Induce Apoptosis in Human Hepatocellular Carcinoma Cell Lines
Cancer Res., April 1, 2000; 60(8): 2085 - 2089.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
M. J. Weyant, A. M. Carothers, M. E. Bertagnolli, and M. M. Bertagnolli
Colon Cancer Chemopreventive Drugs Modulate Integrin-mediated Signaling Pathways
Clin. Cancer Res., March 1, 2000; 6(3): 949 - 956.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.